IP Library Granted Patent US 8,613,958
Granted Patent B2
US 8,613,958 · App. 12/819,670 · Granted Dec 24, 2013

Nitric oxide therapies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,613,958
App. No.
12/819,670
Granted
Dec 24, 2013
Kind
B2
Abstract

A method for delivering nitric oxide therapy to a subject can include administering a composition including a nitric-oxide releasing agent and silica to the subject and releasing a therapeutic amount of nitric oxide from the composition.

Claims (19)

1. A method for delivering nitric oxide therapy to a subject comprising:

exposing a composition including a nitric-oxide releasing agent, silica, and an antioxidant to water in a chamber of a gas delivery device that includes an inlet, an outlet, a particle filter at the outlet, and the chamber,

wherein the nitric-oxide releasing agent is polymeric composition including a polymer and at least one nitric oxide releasing N 2 O 2 − functional group,

administering the gas delivery device to the subject;

generating an air flow through the inlet, the composition in the chamber, and the outlet by subject inhalation; and

releasing a therapeutic amount of nitric oxide from the composition into the air flow.

2. The method of claim 1 , wherein the silica prevents toxic compounds from entering the subject.

3. The method of claim 2 , wherein the antioxidant is ascorbic acid, alpha tocopherol, or gamma tocopherol.

4. The method of claim 1 , wherein the composition is an ointment.

5. The method of claim 1 , wherein the composition is incorporated into an adhesive strip.

6. The method of claim 5 , wherein the adhesive strip has a calibrated scale on one surface thereof for accurate measurement of an ointment dosage.

7. The method of claim 1 , wherein the composition is in the form of a gum or lozenge.

8. The method of claim 1 , wherein the delivery device is an inhaler or nasal cartridge.

9. The method of claim 1 , further comprising a foil backing.

10. The method of claim 5 , wherein the foil backing prevents nitric oxide from being released into an external environment.

11. The method of claim 1 , wherein the therapeutic amount of nitric oxide is at least 1 ppm.

12. The method of claim 1 , wherein the therapeutic amount of nitric oxide is at least 100 ppm.

13. The method of claim 1 , wherein the therapeutic amount of nitric oxide is at least 200 ppm.

14. The method of claim 1 , wherein the therapeutic amount of nitric oxide is at least 300 ppm.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Mar 18, 2026
From: HORIZON TECHNOLOGY FINANCE CORPORATION
To: VERO BIOTECH INC.
Reel/Frame 075308/0198 →
SECURITY INTEREST Recorded Mar 16, 2026
From: VERO BIOTECH INC.
To: SYMBIOTIC CAPITAL AGENCY LLC, AS COLLATERAL AGENT
Reel/Frame 075117/0935 →
TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jan 3, 2024
From: RUNWAY GROWTH FINANCE CORP (F/K/A RUNWAY GROWTH CREDIT FUND INC.)
To: VERO BIOTECH INC. (F/K/A VERO BIOTECH LLC)
Reel/Frame 066186/0611 →
SECURITY INTEREST Recorded Jan 3, 2024
From: VERO BIOTECH INC.
To: HORIZON TECHNOLOGY FINANCE CORPORATION
Reel/Frame 066187/0865 →
CHANGE OF NAME Recorded Feb 14, 2022
From: VERO BIOTECH LLC
To: VERO BIOTECH INC.
Reel/Frame 059085/0418 →
SECURITY INTEREST Recorded Dec 29, 2020
From: VERO BIOTECH LLC
To: RUNWAY GROWTH CREDIT FUND INC.
Reel/Frame 054866/0589 →
CHANGE OF NAME Recorded Jun 6, 2018
From: GENO LLC
To: VERO BIOTECH LLC
Reel/Frame 046304/0855 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2010
From: FINE, DAVID H.
To: GENO LLC
Reel/Frame 024989/0091 →